PMID- 12139943
OWN - NLM
STAT- MEDLINE
DCOM- 20020906
LR  - 20201222
IS  - 1521-6616 (Print)
IS  - 1521-6616 (Linking)
VI  - 104
IP  - 1
DP  - 2002 Jul
TI  - Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated 
      by electrofusion.
PG  - 14-20
AB  - Dendritic cells (DCs) are potent antigen-presenting cells capable of inducing 
      strong immune responses to weak tumor-associated antigens. Among various DC-based 
      approaches, cancer immunotherapy with DC-tumor fusion hybrids offers advantages 
      of polyclonal stimulation of a diverse array of tumor antigens. However, 
      prevalent fusion methods using chemical fusogens such as polyethylene glycol 
      often result in toxicity and low fusion efficiency. In this article, we describe 
      an electrofusion technique, applicable to processing large numbers of cells with 
      consistent and high fusion efficiency. Generation of fusion hybrids was verified 
      by unequivocal experimental evidence. In animal models, fusion hybrids expressed 
      the mature DC-like phenotype. They stimulated both CD4 and CD8 tumor-specific T 
      cells to secrete interferon-gamma in vitro. In immunotherapy, a single 
      vaccination with DC-tumor fusion cells along with interleukin-12 as an adjuvant 
      eradicated tumors established in the skin nd lung. These results provide an 
      impetus for treating cancer patients with similarly generated cells.
FAU - Hayashi, Takashi
AU  - Hayashi T
AD  - Center for Surgery Research, Cleveland Clinic Foundation, Ohio 44195, USA.
FAU - Tanaka, Hiroshi
AU  - Tanaka H
FAU - Tanaka, Junta
AU  - Tanaka J
FAU - Wang, Rongfu
AU  - Wang R
FAU - Averbook, Bruce J
AU  - Averbook BJ
FAU - Cohen, Peter A
AU  - Cohen PA
FAU - Shu, Suyu
AU  - Shu S
LA  - eng
GR  - R01 CA84110/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Antigens, CD)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (CD86 protein, human)
RN  - 0 (Cd86 protein, mouse)
RN  - 0 (Integrin alphaXbeta2)
RN  - 0 (Membrane Glycoproteins)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antigens, CD/immunology
MH  - B7-1 Antigen/immunology
MH  - B7-2 Antigen
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/drug effects/*immunology
MH  - Humans
MH  - Hybrid Cells/*immunology
MH  - Integrin alphaXbeta2/immunology
MH  - Interferon-gamma/metabolism
MH  - Interleukin-12/immunology
MH  - Membrane Glycoproteins/immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Tumor Cells, Cultured
EDAT- 2002/07/26 10:00
MHDA- 2002/09/07 10:01
CRDT- 2002/07/26 10:00
PHST- 2002/07/26 10:00 [pubmed]
PHST- 2002/09/07 10:01 [medline]
PHST- 2002/07/26 10:00 [entrez]
AID - S1521661602952241 [pii]
AID - 10.1006/clim.2002.5224 [doi]
PST - ppublish
SO  - Clin Immunol. 2002 Jul;104(1):14-20. doi: 10.1006/clim.2002.5224.